United States

Evofem Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

USFDA Approves Evofem Biosciences' Phexxi, the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm.

Afaxys Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

TherapeuticsMD and Afaxys Enter Into Agreement

Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: TherapeuticsMD

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 13, 2020

Details:

The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.

Merck & Co. Inc.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Theramex Acquires Commercial Rights for Oral Contraceptive Zoely

Lead Product(s): Estradiol,Nomegestrol Acetate

Therapeutic Area: Obstetrics/Gynecology (Women’s Health)

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 22, 2020

Details:

Theramex currently markets Zoely® in eleven European countries, and this transaction will bring the total number of more than 50 on a global basis. MSD retains rights in the United States and Canada.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Evofem Biosciences

USFDA Approves Evofem Biosciences' Phexxi, the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

Afaxys Pharma

TherapeuticsMD and Afaxys Enter Into Agreement

Merck & Co. Inc.

Theramex Acquires Commercial Rights for Oral Contraceptive Zoely